Kwality Pharmaceuticals Ltd · BSE:KPL
Kwality Pharmaceuticals — H1 FY27 Earnings Presentation
41 slides from Kwality Pharmaceuticals's earnings presentation, Nov 12, 2026
Slide 1: Kwality Pharmaceuticals Ltd Q2 & H1 FY27 Investor Presentation
Kwality Pharmaceuticals Ltd Q2 & H1 FY27 Investor Presentation
Slide 2: Disclaimer
DISCLAMER Some of the statements made in this presentation are forward-looking statements and are based on the current beliefs, assumptions, expectations, estimates, objectives and projections of the directors and management of Kwality Pharmaceutical Limited about its business, the industry and mark
Slide 3: Q2FY27 Financial Performance
Q2FY27 Financial Performance Confidential & For Limited Circulation Only
Slide 4: Solid execution reflected in Q2FY27
Solid execution reflected in Q2FY27 Revenue EBITDA and Margins (%) PAT and Margins (%) 162 181 50 29 26 41 25.3% 27.5% 15.7% 16% Q1FY27 Q2FY27 Q1FY27 Q2FY27 Q1FY27 Q2FY27 Revenue EBITDA and Margins (%) PAT and Margins (%) 181 50 29 111 25 14 23.4% 27.5% 13% 16% Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2F
Slide 5: Performance drivers for Q2FY27
Performance drivers for Q2FY27 01 Expansion in Regulated Markets 02 Regulatory & Compliance Milestones New registrations secured across LATAM (incl. Mexico, Colombia), MENA, GCC, and EU-GMP certification received from Hungary for Cephalosporin and Oncology plants select Asian markets including Malay
Slide 6: FY27 Guidance Tracker – H1FY27 Progress
FY27 Guidance Tracker – H1FY27 Progress FY27 revenue guidance revised upward to ₹720+ Cr (from ₹700+ Cr) FY26A FY27 Guidance FY27 GUIDANCE Q1FY27 Q2FY27 METRIC (Actual) given earlier (Revised from ₹700+ Cr) (Actual) (Actual) REVENUE 503 700 720+ 162.4 181.2 (₹ Crore) (+43%+) (+11% QoQ) EBITDA 118 18
Slide 7: Profit and Loss Statement - Q2FY27
Profit and Loss Statement - Q2FY27 Particulars Q2FY27 Q1FY27 QoQ Q2FY26 YoY Revenue from operations (Net) 181.2 162.4 12% 111.0 62% (a) Cost of materials consumed 81.7 85.3 -4% 54.0 51% (b) Purchases of stock-in-trade 6.8 0.5 1260% 1.0 580% (c) Changes in inventories of finished goods work - in - pr
Slide 8: Balance Sheet
Balance Sheet Particulars (In INR Cr.) FY23 FY24 FY25 FY26 H1FY27 Particulars (In crs) FY23 FY24 FY25 FY26 H1FY27 ASSETS 354 394 447 592 EQUITY & LIABILITIES 354 394 447 592 698 Equity Non-current assets 146 152 163 186 218 Share Capital 10 10 10 10 10 Other Equity 190 214 254 322 376 Property Plant
Slide 9: Working Capital Ratios: Cash Conversion Cycle Down to 130 Days
Working Capital Ratios: Cash Conversion Cycle Down to 130 Days Since FY23 Tighter inventory and receivables discipline is releasing cash as the business scales Debtor days* Inventory days Payable days Cash conversion cycle 178 days 77 days 126 days 130 days FY26: 203 → H1FY27: 178 FY26: 111 → H1FY27
Slide 10: Q2FY27 Business Updates
Q2FY27 Business Updates Confidential & For Limited Circulation Only
Slide 11: Appointment of KPMG
Appointment of KPMG Strengthening governance and systems for the next phase of growth KPMG appointed 01 Kwality Pharmaceuticals has engaged KPMG as its Statutory Auditor. Why now 02 To further strengthen the Company’s corporate governance and financial reporting practices in line with its growing in
Slide 12: Global Development Programme: 40 Products in the Pipeline
Global Development Programme: 40 Products in the Pipeline Global Development Programme – BE and dossier status across Oncology, General and Beta Lactam portfolios Products in Dossiers ready for BE studies completed Dossiers in progress 40 development 11 Oncology · 27 General · 2 Beta Lactam 19 incl.
Slide 13: Key Products across Portfolio
Key Products across Portfolio Generic Oncology Anti-infectives Units 1 & 2 · cardio-metabolic, anti-diabetic, anti-infective Unit 3 · oral solids and complex injectables Beta Lactam & Cephalosporins (Unit 4) · injectables and orals Empagliflozin + Linagliptin + Sacubitril + Valsartan Nilontinib Caps
Slide 14: New Launches
New Launches New launches extend the portfolio into biologics, antiretrovirals, ophthalmics and critical care Pembrolizumab Erythropoietin Filgrastim Sodium Hyaluronate Biologics · injection 100 mg/4 ml Biologics · pre-filled syringe 2000 IU Biologics · injection 300 mcg/0.5 ml Eye Drops Kwali-Ralt
Slide 15: Unit 6- Hormone Facility Update
Unit 6- Hormone Facility Update Construction Update & Commissioning Roadmap Completion Tracker Key Milestones Civil Construction 100% ✓ Construction commenced Q2 FY26 Equipment Procurement 100% ✓ Equipment order placed Q3 FY26 Equipment Installation 100% ✓ Major equipment installed Q1 FY27 Utilities
Slide 16: Biologics & Hormones: Building the Next Growth Engines
Biologics & Hormones: Building the Next Growth Engines Strategic capacity additions expand Kwality beyond traditional formulations into high-entry-barrier specialty products. PLACEHOLDER Hormone Facility Photo Development Status Construction Progress WHO-GMP biologics facility established Dedicated
Slide 17: Business Overview
Business Overview Confidential & For Limited Circulation Only
Slide 18: 4 Decades of Expertise and Manufacturing Excellence
4 Decades of Expertise and Manufacturing Excellence Future Growth: High Margin critical Research + Manufacturing + Quality Excellence Achieved Expertise in Complex Formulation care, Bio-similar and oncology Development & Manufacturing molecules including peptides 01 2,200+ employees including 80+ in
Slide 19: Revenue growth supported by manufacturing scale-up
Revenue growth supported by manufacturing scale-up All values in INR Cr. CAGR : 26% 720+ 503 370 307 251 FY23 FY24 FY25 FY26 FY27E Journey so far… 1983 2018 2020 2022 2023 2024 2025 2026 Company • Manufacturing • Migrated • Established • Established • Initiated • PICs GMP • EUGMP (Hungary) approval
Slide 20: Leadership backed by Experience
Leadership backed by Experience Ramesh Arora Ajay Arora Aditya Arora Chairman & Managing Director Director Director AREA OF FOCUS AREA OF FOCUS AREA OF FOCUS IT, Software and Legal Raw material procurement and Agreements & Proceedings Quality assurance, Quality infrastructure development control, Re
Slide 21: PAT growing ~3.5x faster than revenue
PAT growing ~3.5x faster than revenue Revenue Scale Translating into Profit Acceleration Key Levers and their performance over years Key Operational FY23 FY26 H1FY27 67 Levers Revenue (₹ Cr) 251 503 344 40 Cumulative Filings 24 503 75 700+ 750+ (Nos.) 370 307 Capacity Utilisation 200 ~35% ~65%+ ~70%
Slide 22: Low leverage and strong coverage - significant headroom for capex
Low leverage and strong coverage - significant headroom for capex 0.98 1.84 0.44 0.43 1.8 0.96 0.41 0.39 1.67 0.38 0.38 0.38 0.88 0.37 1.60 0.86 Gross Debt/Equity Net Debt/Equity Current ratio Asset turnover FY24 FY25 FY26 H1FY27 FY24 FY25 FY26 H1FY27 FY24 FY25 FY26 H1FY27 1.81 14.47 0.92 1.79 0.81
Slide 23: 4/5 units being EU-GMP approved
4/5 units being EU - GMP approved Unit 3 : Oncology – Capacity expansion to be completed by June 2027 Unit 6 : Hormones – construction completed, Manufacturing audit triggered Unit 7 : Mega General plant – land acquired Unit 1 : General Unit 3 : Oncology Unit 5: Biologics (To be commenced by FY29) E
Slide 24: Comprehensive Offerings with Advanced Manufacturing Capabilities
Comprehensive Offerings with Advanced Manufacturing Capabilities Amritsar Plant (Campus 1) Himachal plant (Campus 2) Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 ` Unit 7 (General) (Beta Lactam) (Oncology) (Cephalosporins) (Biologics) (Hormones) Oral Solids - Tab/Capsule, Oral Solids - Suppositories Or
Slide 25: What sets us apart?
What sets us apart? 02 03 01 Diversified portfolio across Open and Flexible Business Model, Globally accredited, strong high entry barrier dosage Powered by in house R&D capabilities manufacturing capabilities forms.. for complex molecule development. 04 05 Wide Presence Healthy Balance sheet provid
Slide 26: 1000+ products across key therapies - Broad Dosage form capabilities
1000+ products across key therapies - Broad Dosage form capabilities Revenue Types Therapies share % Unit wise Revenue Split Generals, Beta Lactam, Oncology & Injectables 46% Cephalosporins 63% 61% Generals, Beta Lactam, Oncology & Tablets 38% Cephalosporins Generals, Beta Lactam, Oncology & Capsule
Slide 27: Out-Licensing & Supply: Asset-Light Global Market Access
Out-Licensing & Supply : Asset - Light Global Market Access Revenue share Strategic Partnerships Filings 10% 200 175 140 75 90% 100+ clients across LATAM, MENA, Europe, Asia & Africa; FY23 FY24 FY25 FY26 expand via 700+ filings. Outlicensing and Supply CDMO Filings Tie to Moats Leverage achieved Regu
Slide 28: CDMO: End-to-End Partnership Driving High-Value Growth
CDMO: End-to-End Partnership Driving High-Value Growth..contd Metric Kwality Stats Benefits Boosting talent, attaining expertise 80 scientists Proves innovation R&D Headcount (DSIR-recognized) muscle 214 Dedicated QA and QC QA & QC team teams function 188 170+; 210+ strength independently across eac
Slide 29: Core Research Initiatives
Applied R&D + Development Engine supporting future CDMO partnerships Core Research Initiatives 01 Biosimilars Development Building end-to-end biologics development and analytical capabilities to support future biosimilar launches and biologics CDMO engagements. Hypothesis driven innovation 02 Enhanc
Slide 30: Differentiated Capabilities
Differentiated Capabilities Lyophilized Injectables Emulsion • Solubility via Freeze - drying Long - acting Technology • Improved Stability Injectables • Fast Absorption • Sustained Drug Release • Low Globule Size • Peptide-based Injections • Low Osmolaity • Polymeric Microspheres Liposomal Pegylate
Slide 31: Export led growth strategy
Export led growth strategy Asia Europe GCC/MENA Operating in 70+ Markets RU/CIS South and Africa Middle East Central America 31
Slide 32: Global Accreditations
Global Accrediations and many more... 32
Slide 33: Working Capital Normalizing with Scale, Improving Capital Productivity
Working Capital Normalizing with Scale, Improving Capital Productivity 297 232 31.0% 231 217 208 196 200 31.0% 189 28.4% 161 162 130 126 22% 22.7% 114 111 19% 77 15% 11% Cash conversion days Inventory days payable days FY24 FY25 FY26 H1FY27 ROE ROCE FY23 FY24 FY25 FY26 H1FY27 Massive Improvement in
Slide 34: FY27–FY29 Growth Roadmap
FY27–FY29 Growth Roadmap Confidential & For Limited Circulation Only
Slide 35: Scaling to next orbit: INR 720+ Cr FY27 revenue milestone
Scaling to next orbit : INR 720+ Cr FY27 revenue milestone Action plan for the next two years Expanding to high margin Revenue Target : INR 720+ Cr. Unlocking Regulated Market Upside specialty platforms Through EU-GMP Readiness EBITDA : ~INR 189-196 Cr. EBITDA Margin : 27-28% PAT: INR720 122 Cr. 4 o
Slide 36: Scaling to next orbit: INR 1000+ Cr FY29 revenue milestone
Scaling to next orbit : INR 1000+ Cr FY29 revenue milestone Expanding to high margin specialty platforms Commercialize its first biologic, Erythropoietin, in H1 of the next financial year, while continuing to build its presence in complex and niche injectable manufacturing. Expected Outcome Margins
Slide 37: FY23–FY26 Financial Track Record
FY23–FY26 Financial Track Record Confidential & For Limited Circulation Only
Slide 38: Historical Statement of Profit & Loss
Historical Statement of Profit & Loss Particulars FY23 FY24 FY25 FY26 Revenue from operations (Net) 251 307 370 503 (a) Cost of materials consumed 113 154 165 241 (b) Purchases of stock-in-trade 0 1 16 17 (c) Changes in inventories of finished goods work - in - progress and stock - in - trade -3 -1
Slide 39: Balance Sheet
Balance Sheet Particulars (In INR Cr.) FY23 FY24 FY25 FY26 Particulars (In crs) FY23 FY24 FY25 FY26 ASSETS 354 394 447 592 EQUITY & LIABILITIES 354 394 447 592 Equity Non-current assets 146 152 163 186 Share Capital 10 10 10 10 Other Equity 190 214 254 322 Property Plant & Equipment 120 139 144 150
Slide 40: Cash Flow Statement
Cash Flow Statement Particulars FY23 FY24 FY25 FY26 Cashflow from Operating Ac vi es 41.38 42.98 52.72 16.59 Cashflow from Investing Ac vi es (48.44) (26.39) (28.52) (34.90) Cashflow from Financing Ac vi es 0.99 (17.39) (14.44) 7.03 Cash and Cash Equivalents as at end of period/Year 3.07 2.26 12.02
Slide 41: Thank You
THANK YOU Kwality Pharmaceuticals Ltd. Head Office Address : 6th Milestone, Majitha Road, Amritsar-143601, Punjab, India Company Contact: Ujjval Seth [email protected] Investor Relations Contact: Go India Advisors Soumya Chhajed [email protected]
Kwality Pharmaceuticals — H1 FY27 Earnings Presentation on 6ix